Deoxycholic acid Injection
DrugOther names: ATX-101
NCT Number: NCT01294644
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 3
Investigational Site, Geel, Belgium
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: ATX-101
Phosphate buffered saline placebo for injection
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment.
The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment.
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
A negative change from Baseline indicates improvement.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.
A positive change from Baseline indicates improvement.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Submental thickness was measured using caliper devices.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
The PR-SMFRS is based on the participant's response to the question "How much fat do you currently have under your chin?" answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. Improvement is defined as any decrease in score and worsened as any increase in score.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
The PR-SMFIS assesses the impact of submental fat on self-perception of 6 characteristics related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions:
How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?" Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive.
A positive change from Baseline indicates improvement.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Kythera Biopharmaceuticals
Industry
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05266729
Hemic and Lymphatic Diseases, Immune System Diseases
Seoul, South Korea
View Trial DetailsNCT03982225
Hemic and Lymphatic Diseases, Immune System Diseases
Seongnam-si, Gyeonggi-do, South Korea
View Trial DetailsNCT01426373
Hemic and Lymphatic Diseases, Immune System Diseases
Beverly Hills, California, United States
View Trial DetailsNCT02007434
Hemic and Lymphatic Diseases, Immune System Diseases
Tempe, Arizona, United States
View Trial Details